SLC5A2 and chronic kidney disease: The DAPA-CKD study and the SCORED study showed that even in patients with a reduced estimated glomerular filtration (eGFR) as low as 25 ml/min/1.73 m2, SGLT2 inhibitors still conferred the benefit of a reduction in HHF without worsening renal function.